Article: Aldara(TM) (Imiquimod) Cream, 5% Included in More Than 20 Presentations at American Academy of Dermatology's 64th Annual Meeting.

ST. PAUL, Minn. -- 3M (NYSE:MMM):

--Aldara is the First and Only Immune Response Modifier Indicated for the Treatment of Actinic Keratosis, Superficial Basal Cell Carcinoma and External Genital Warts

3M announced today that Aldara Cream is a featured topic in more than 20 presentations by leading researchers at the upcoming American Academy of Dermatology's (AAD) 64th annual meeting in San Francisco, March 3-7. Aldara Cream is the first and only immune response modifier indicated for the treatment of precancerous actinic keratosis, superficial basal cell carcinoma and external genital and perianal warts. The prescription therapy works by stimulating the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!